NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

OSTEOPORE LIMITED (OSX)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 

Shareholder links

Our website ranking of OSX: rating 4
(4 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Group
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail

Company details

ISIN: AU0000053324
Address: Level 5, 191 St. Georges Terrace Perth WA 6000
Tel:  +61 2 8072 1400

Date first listed: 23/09/2019
Company Secretary: Kellie Davis
Activities: Production of 3D printed bioresorbable implants that are used conjunction with surgical procedures to assist with the natural stages of bone replacement

News & Events

Expand this box to read and print

The suspension of trading in the securities of Osteopore Limited will be lifted from the commencement of trading on Wednesday, 17 April 2024 following lodgement of its Annual Report for the year ended 31 December 2023.

16/04/2024

The company lodges its Annual Report to Shareholders.

16/04/2024

The company releases its Appendix 4G and Corporate Governance Statement.

16/04/2024

The company releases a response to ASX Query Letter.

15/04/2024

The maturity date of the Bridging Loan was ninety calendar days from the disbursement date. The Company has entered a variation deed on 9 April 2024 with the Lender to extend the maturity date of the Bridging Loan to 1 May 2025. The Bridging Loan interest rate under the Variation Deed has changed from 3% per month in the initial three months, 4% per month in the fourth month and 5% per month in the fifth month and thereafter, to 3% per month calculated on a daily rest basis and payable on the first business day of each month. Notwithstanding any other provisions to the Variation Deed, the Company has the option to make early repayments to the Bridging Loan at any time. Other Bridging Loan terms and conditions remain unchanged.

10/04/2024

The company's AGM will be held on 30 May 2024. Any nominations for directors must be received at the company's registered office no later than 5:00pm (WST) on 18 April 2024.

08/04/2024

The company's AGM will be held on 30 May 2024. Any nominations for directors must be received at the company's registered office no later than 5:00pm (WST) on 18 April 2024.

08/04/2024

The company releases an updated notice of proposed issue of securities.

05/04/2024

The Renounceable Pro-Rata Entitlement Offer and Shortfall Offer to raise ~A$3,000,000 (before costs) closed on 2 April 2024 with strong support from eligible shareholders.

05/04/2024

The company releases an updated notice of proposed issue of securities.

04/04/2024

The company releases a replacement prospectus for Renounceable Rights Issue.

04/04/2024

The company releases a notice of proposed issue of securities.

02/04/2024

The company releases a letter to its eligible shareholders regarding the entitlement offer.

02/04/2024

The Company releases a replacement entitlement offer prospectus for a renounceable pro rata offer to Eligible Shareholders of approximately 103,286,890 New Shares at an issue price of $0.029 per New Share on the basis of 10 New Share for every 1 Existing Shares with 1 free attaching New Option for every 5 New Shares acquired to raise up to $3,000,000 before costs. This Prospectus is also being issued for the Shortfall Offer described in this Prospectus.

02/04/2024

The securities of the Company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed.

02/04/2024

The securities of the Company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed.

02/04/2024

The securities of Osteopore Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OSX, pending the release of its Annual Report.

28/03/2024

The suspension of the following options of Osteopore Limited ("˜will be lifted immediately following ASX being satisfied that there is a sufficient spread of option holders for the purposes of Listing Rule 2.5 condition 6: OSXO

26/04/2023

The following Options of Osteopore Limited will be suspended from quotation immediately under Listing Rule 17.3: OSXO.

24/04/2023

The suspension of trading in the securities of Osteopore Limited will be lifted immediately following the release by OSX of an announcement regarding a capital raising.

22/12/2022

The company releases a notice of proposed issue of securities.

22/12/2022

Osteopore has received binding commitments from sophisticated and existing investors for a total A$1,000,000 Placement at $0.15 per share, with one (1) free attaching option for every one (1) new share subscribed for. Proceeds from the Placement will be used to support sales momentum, develop and launch new breakthrough products, secure regulatory clearances in new markets and provide capacity for continued exploration of potential partnerships and acquisition opportunities aimed at increasing company value. The Company has entered into a non-binding term sheet with Mr Lim Jae Hoon for the proposed acquisition of 100% of the businesses owned by Lomic Korea Co., Ltd, 3D Aesthetic Solutions Pte Ltd, 3D Healthcare Solutions Co., Ltd and 3D Aesthetic Medical Equipment and Supplies Trading in order to increase the distribution of Osteopore products.

22/12/2022

The securities of Osteopore Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OSX, pending the release of an announcement regarding a capital raising.

21/12/2022

listed entity carried for record purposes only

23/09/2019

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    04/07/2023Mark Leong325,000$0.049$15,939
    30/06/2022Mark Leong150,000$0.106$15,850
    10/06/2022Swee Hin Teoh100,000$0.155$15,541

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Mark LeongExecutive Chairman, Independent Director02/08/2021
    Lim JingCEO01/05/2022
    Daniel OwIndependent Director08/10/2021
    Swee Hin TeohNon Exec Director23/09/2019
    Michael KeenanNon Exec Director18/07/2023

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Khoon Seng GohCEO23/09/201913/07/2023
    Vlado BosanacIndependent Director29/12/202114/02/2022
    Carl RundeCFO02/11/202018/01/2022
    Stuart CarmichaelNon Exec Director23/09/201907/10/2021
    Geoff PocockNon Exec Director23/09/201907/10/2021
    Brett SandercockNon Exec Chairman23/09/201901/08/2021

    Date of first appointment, title may have changed.